RT Journal Article
SR Electronic
T1 P255 Once-daily Tiotropium Respimat® Add-on To At Least Ics Maintenance Therapy Reduces Exacerbation Risk In Patients With Uncontrolled Symptomatic Asthma
JF Thorax
JO Thorax
FD BMJ Publishing Group Ltd and British Thoracic Society
SP A189
OP A189
DO 10.1136/thoraxjnl-2014-206260.383
VO 69
IS Suppl 2
A1 Halpin, DMG
A1 Paggiaro, P
A1 Bleecker, E
A1 Engel, M
A1 Moroni-Zentgraf, P
A1 Schmidt, H
A1 Kerstjens, HAM
YR 2014
UL http://thorax.bmj.com/content/69/Suppl_2/A189.1.abstract
AB Background A reduction in asthma exacerbation risk may provide improvements in clinical burden, patient experience and healthcare costs. In Phase III trials, once-daily tiotropium (delivered via the Respimat® SoftMist™ inhaler) added on to at least inhaled corticosteroids (ICS) improved lung function in patients with symptomatic asthma. We investigated exacerbation risk in each trial. Methods Five Phase III, double-blind, placebo-controlled, parallel-group trials in patients with symptomatic asthma. Patients received tiotropium Respimat® 5 µg or placebo as add-on to at least ICS maintenance therapy (Table). Pre-planned co-primary or secondary end points were time to first severe exacerbation and time to any asthma worsening. Results Mean baseline% of predicted forced expiratory volume in 1 second, seven-question Asthma Control Questionnaire score and ICS dose (µg) were: 56.0 ± 13.1, 2.6 ± 0.7, 1198 ± 539 (PrimoTinA-asthma®); 75.1 ± 11.5, 2.2 ± 0.5, 660 ± 213 (MezzoTinA-asthma®); 77.7 ± 11.9, 2.1 ± 0.4, 381 ± 78 (GraziaTinA-asthma®). Tiotropium Respimat® 5 µg reduced severe asthma exacerbation risk by at least 21% in all three severity cohorts (Table) and asthma worsening risk versus placebo in all trials, with a statistically significant reduction in the PrimoTinA-asthma® trial. Conclusion Once-daily tiotropium Respimat® 5 µg add-on to at least ICS maintenance therapy consistently reduced exacerbations across asthma severities and so may be a beneficial add-on option to reduce current and future exacerbation risk.